Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: TSE:I
- CUSIP: N/A
- Web: N/A
Average Prices:- 50 Day Moving Avg: C$3.41
- 200 Day Moving Avg: C$3.41
- 52 Week Range: C$1.78 - C$4.50
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Profitability:- Net Margins: -90.20%
- Return on Equity: -863.26%
- Return on Assets: -92.01%
Misc:- Average Volume: 15,974 shs.
Frequently Asked Questions for IntelliPharmaCeutics International (TSE:I)
What is IntelliPharmaCeutics International's stock symbol?
IntelliPharmaCeutics International trades on the Tornton Stock Exchange (TSX) under the ticker symbol "I."
How were IntelliPharmaCeutics International's earnings last quarter?
IntelliPharmaCeutics International Inc. (TSE:I) issued its quarterly earnings results on Monday, April, 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.03 by $0.07. The business earned $5.14 million during the quarter, compared to analyst estimates of $3.63 million. IntelliPharmaCeutics International had a negative return on equity of 863.26% and a negative net margin of 90.20%. View IntelliPharmaCeutics International's Earnings History.
When will IntelliPharmaCeutics International make its next earnings announcement?
Who are some of IntelliPharmaCeutics International's key competitors?
Some companies that are related to IntelliPharmaCeutics International include Colliers International Group (CIG), Kirkland Lake Gold Ltd (NMI), Osisko Mining Corp (OBM), Royal Bank of Canada (RY), Toronto-Dominion Bank (TD), Bank of Nova Scotia (BNS), Enbridge (ENB), Canadian National Railway Company (CNR), Suncor Energy (SU), Bank of Montreal (BMO), TransCanada (TRP), BCE (BCE), Manulife Financial Corp. (MFC), Canadian Natural Resources Limited (CNQ), Canadian Imperial Bank of Commerce (CM), Thomson Reuters Corp (TRI), Great-West Lifeco (GWO) and Imperial Oil Ltd (IMO).
Who are IntelliPharmaCeutics International's key executives?
IntelliPharmaCeutics International's management team includes the folowing people:
- Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
- Amina Odidi Ph.D., President, Chief Operating Officer, Director
- Domenic Della Penna, Chief Financial Officer
- John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
- Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
- Kenneth Keirstead, Independent Director
- Bahadur Madhani, Independent Director
- Eldon R. Smith M.D., Independent Director
How do I buy IntelliPharmaCeutics International stock?
Shares of IntelliPharmaCeutics International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is IntelliPharmaCeutics International's stock price today?
One share of IntelliPharmaCeutics International stock can currently be purchased for approximately C$3.23.
MarketBeat Community Rating for IntelliPharmaCeutics International (TSE I)MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for IntelliPharmaCeutics International (TSE:I) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for IntelliPharmaCeutics International (TSE:I)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for IntelliPharmaCeutics International (TSE:I)Earnings History by Quarter for IntelliPharmaCeutics International (TSE I)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/12/2017 | | | | | | | | |
| 4/14/2014 | | $0.03 | $0.10 | $3.63 million | $5.14 million | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for IntelliPharmaCeutics International (TSE:I)Current Year EPS Consensus Estimate: $0.23 EPS
Dividend History for IntelliPharmaCeutics International (TSE:I)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for IntelliPharmaCeutics International (TSE:I)Insider Trades by Quarter for IntelliPharmaCeutics International (TSE:I)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/30/2015 | Penna Domenic Della | Insider | Buy | 3,510 | C$2.10 | C$7,371.00 | |
| 11/25/2015 | Penna Domenic Della | Insider | Buy | 20,375 | C$1.87 | C$38,101.25 | |
| 10/29/2015 | Bahadur Madhani | Director | Buy | 1,000 | C$2.42 | C$2,420.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for IntelliPharmaCeutics International (TSE:I)
Latest Headlines for IntelliPharmaCeutics International (TSE:I)
| Source: |
|
IntelliPharmaCeutics International (I) Chart for Sunday, August, 20, 2017
